Boehringer Ingelheim Vetmedica Gmbh

Other

United States of America, As Represented by the Secretary of Agriculture

United States Department of Agriculture

Mike Roof

Jeremy Kroll

David E Gorcyca

Kelly M Lager

William L Mengeling

Ann C Vorwald

Kelly Burkhart

Kelly Lager

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Immunogenic compositions comprising

[object Object]

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.

Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142

Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation.

Growing community of inventors

Ames, IA, United States of America

Mike Roof